Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study

Documenti analoghi

• Effects of higher and more frequent dosing of alglucosidase alfa and immunomodulation on long‐term clinical outcome of classic infantile Pompe patients
  di: Poelman, Esther, et al.
  Pubblicazione: (2020)
• Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
  di: Kanters, Tim A, et al.
  Pubblicazione: (2014)
• A higher dose of enzyme therapy in patients with classic infantile Pompe disease seems to improve ventilator-free survival and motor function
  di: van Gelder, C, et al.
  Pubblicazione: (2013)
• Enzyme therapy and immune response in relation to CRIM status: the Dutch experience in classic infantile Pompe disease
  di: van Gelder, Carin M., et al.
  Pubblicazione: (2014)
• Antibody formation to enzyme therapy in classic infantile Pompe disease: implications of patient age
  di: van Gelder, C, et al.
  Pubblicazione: (2013)